Proteome Sciences PLC Repayment of Loan (3395B)

TIDMPRM

RNS Number : 3395B

Proteome Sciences PLC

01 June 2023

1 June 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Repayment of Loan to Vulpes Investment Management Private Limited

The Directors of Proteome are pleased to announce that the Company has today repaid in full the outstanding loan and associated interest (together totalling GBP824,424) to Vulpes Investment Management Private Limited originally announced on 2 July 2018 and amended on 30 March 2022.

 
 
   Proteome Sciences plc 
 Dr. Mariola Soehngen, Chief Executive Officer   Tel: +44 (0)20 7043 2116 
  Dr. Ian Pike, Chief Scientific Officer 
 Richard Dennis, Chief Commercial Officer 
  Abdelghani Omari, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter (Corporate      Tel: +44 (0) 20 3328 5656 
  Finance) 
  Tony Quirke / Stefano Aquilino (Equity 
  Sales & Corporate Broking)

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFIFSTRIILIIV

(END) Dow Jones Newswires

June 01, 2023 04:43 ET (08:43 GMT)

Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024